Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 07 2022 - 5:30AM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced that Marty Huber, M.D.,
president of research and development and chief medical officer,
will present at the 21st Annual Needham Virtual Healthcare
Conference on Thursday, April 14, 2022, at 8:00 a.m. ET.
A live webcast will be available in the Investors and Media
section of the Xilio Therapeutics’ website at
https://ir.xiliotx.com. A replay of the webcast will be archived on
Xilio Therapeutics’ website for 30 days following the
presentation.
About Xilio TherapeuticsXilio Therapeutics is a
clinical-stage biotechnology company focused on harnessing the
immune system to achieve deep and durable clinical responses to
improve the lives of patients with cancer. The company is using its
proprietary geographically precise solutions (GPS) platform to
rapidly engineer novel molecules, including cytokines and other
biologics, that are designed to optimize their therapeutic index.
These molecules are designed to localize activity within the tumor
microenvironment without systemic effect, resulting in the
potential to achieve enhanced anti-tumor activity. Xilio is
building a pipeline of wholly owned, tumor-selective, GPS-enabled
cytokine and checkpoint inhibitor product candidates, including its
clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4
monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as
its earlier pipeline, including XTX301, a tumor-selective IL-12,
and XTX401, a tumor-selective IL-15. For more information, please
visit www.xiliotx.com.
For Investor Inquiries: Chelcie Lister, THRUST
Strategic Communicationschelcie@thrustsc.com
For Media Inquiries: Dan
Budwickdan@1abmedia.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2024 to May 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From May 2023 to May 2024